FILE - Packaging for AbbVie's drug, Humira, is photographed in Houston on July 18, 2014. Patients who take the autoimmune disease treatment may see some price relief when several lower-cost ...

An illustration of the packaging for Amgen Inc's Amjevita as well as the 40 milligram auto injector containing a bio similar version of AbbVie's Inc's Humira ...

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings? Lowering drug prices for ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives ...

WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less ...

UnitedHealth Group’s pharmacy benefit manager Optum Rx Tuesday said it will put three less expensive “biosimilar” versions of Abbvie’s pricey rheumatoid arthritis drug Humira “in the sam ...

Investors certainly are. It has now been several months since a copycat version of the arthritis therapy Humira—the highest-grossing drug ever—was launched. For now, doctors are still mostly ...

Humira, AbbVie’s blockbuster immunology drug, is finally facing competition from copycats. It really needs its other drugs to start chipping in. Yet newer immunology drugs Skyrizi and Rinvoq ...

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. Credit...Nic Antaya for The New York Times Supported ...

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. But lower ...